These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 36837928)

  • 81. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
    Khoo SH; FitzGerald R; Saunders G; Middleton C; Ahmad S; Edwards CJ; Hadjiyiannakis D; Walker L; Lyon R; Shaw V; Mozgunov P; Periselneris J; Woods C; Bullock K; Hale C; Reynolds H; Downs N; Ewings S; Buadi A; Cameron D; Edwards T; Knox E; Donovan-Banfield I; Greenhalf W; Chiong J; Lavelle-Langham L; Jacobs M; Northey J; Painter W; Holman W; Lalloo DG; Tetlow M; Hiscox JA; Jaki T; Fletcher T; Griffiths G;
    Lancet Infect Dis; 2023 Feb; 23(2):183-195. PubMed ID: 36272432
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity.
    Hadj Hassine I; Ben M'hadheb M; Menéndez-Arias L
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458571
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-
    Dinda B; Dinda S; Dinda M
    Phytomed Plus; 2023 Feb; 3(1):100402. PubMed ID: 36597465
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.
    Vangeel L; Chiu W; De Jonghe S; Maes P; Slechten B; Raymenants J; André E; Leyssen P; Neyts J; Jochmans D
    Antiviral Res; 2022 Feb; 198():105252. PubMed ID: 35085683
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Two short approaches to the COVID-19 drug β-D-
    Persaud KE; Sahu RR; Neary MC; Kapdi AR; Lakshman MK
    Org Biomol Chem; 2024 Jan; 22(4):735-740. PubMed ID: 38168802
    [TBL] [Abstract][Full Text] [Related]  

  • 86. SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model.
    Lieber CM; Cox RM; Sourimant J; Wolf JD; Juergens K; Phung Q; Saindane MT; Smith MK; Sticher ZM; Kalykhalov AA; Natchus MG; Painter GR; Sakamoto K; Greninger AL; Plemper RK
    Nat Commun; 2022 Jul; 13(1):4416. PubMed ID: 35906230
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial.
    Strizki JM; Grobler JA; Murgolo N; Fridman A; Johnson MG; Du J; Carmelitano P; Brown ML; Paschke A; De Anda C
    Infect Dis Ther; 2023 Dec; 12(12):2725-2743. PubMed ID: 37995070
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Safety of RNA-Dependent RNA Polymerase Inhibitors, Molnupiravir and VV116, for Oral Treatment of COVID-19: A Meta-Analysis.
    Zheng Z; Zhou J; Song Y
    Iran J Med Sci; 2024 May; 49(5):275-285. PubMed ID: 38751873
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.
    Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R
    Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504
    [No Abstract]   [Full Text] [Related]  

  • 90. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
    Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
    JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Synergistic Antiviral Activity of Pamapimod and Pioglitazone against SARS-CoV-2 and Its Variants of Concern.
    Setz C; Große M; Auth J; Fröba M; Rauch P; Bausch A; Wright M; Schubert U
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743273
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Real-world effectiveness of molnupiravir, azvudine and paxlovid against mortality and viral clearance among hospitalized patients with COVID-19 infection during the omicron wave in China: A retrospective cohort study.
    Chen Y; Lin Y; Lu H; Wu X; Pan Y; Xia A; Pang L; Ye W; Xu F
    Diagn Microbiol Infect Dis; 2024 Aug; 109(4):116353. PubMed ID: 38776665
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The Omicron Variant BA.1.1 Presents a Lower Pathogenicity than B.1 D614G and Delta Variants in a Feline Model of SARS-CoV-2 Infection.
    Martins M; do Nascimento GM; Nooruzzaman M; Yuan F; Chen C; Caserta LC; Miller AD; Whittaker GR; Fang Y; Diel DG
    J Virol; 2022 Sep; 96(17):e0096122. PubMed ID: 36000850
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Molnupiravir in COVID-19: A Scoping Review.
    Kaore S; Atal S
    Curr Drug Res Rev; 2022; 14(3):203-214. PubMed ID: 35638286
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Effects of natural polymorphisms in SARS-CoV-2 RNA-dependent RNA polymerase on its activity and sensitivity to inhibitors in vitro.
    Miropolskaya N; Kozlov M; Petushkov I; Prostova M; Pupov D; Esyunina D; Kochetkov S; Kulbachinskiy A
    Biochimie; 2023 Mar; 206():81-88. PubMed ID: 36252889
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Evaluation of a series of nucleoside analogs as effective anticoronaviral-2 drugs against the Omicron-B.1.1.529/BA.2 subvariant: A repurposing research study.
    Rabie AM; Abdalla M
    Med Chem Res; 2023; 32(2):326-341. PubMed ID: 36593869
    [TBL] [Abstract][Full Text] [Related]  

  • 97. The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses.
    Martinez DR; Moreira FR; Catanzaro NJ; Diefenbacher MV; Zweigart MR; Gully KL; De la Cruz G; Brown AJ; Adams LE; Yount B; Baric TJ; Mallory ML; Conrad H; May SR; Dong S; Scobey DT; Nguyen C; Montgomery SA; Perry JK; Babusis D; Barrett KT; Nguyen AH; Nguyen AQ; Kalla R; Bannister R; Feng JY; Cihlar T; Baric RS; Mackman RL; Bilello JP; Schäfer A; Sheahan TP
    Sci Transl Med; 2024 May; 16(748):eadj4504. PubMed ID: 38776389
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Molnupiravir: First Approval.
    Syed YY
    Drugs; 2022 Mar; 82(4):455-460. PubMed ID: 35184266
    [TBL] [Abstract][Full Text] [Related]  

  • 99. SARS-CoV-2 replication and drug discovery.
    Nazir F; John Kombe Kombe A; Khalid Z; Bibi S; Zhang H; Wu S; Jin T
    Mol Cell Probes; 2024 Oct; 77():101973. PubMed ID: 39025272
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.